Transcription Factors E2F2/3/4 As Possible Colorectal Cancer Prognostic Biomarkers

Wen-Da Wang,Li-Chun Wang,Mao-Xi Liu,Yan-Jun Lu,Bo Jiang

DOI: https://doi.org/10.21203/rs.3.rs-528292/v1

2021-06-02

Abstract:Abstract Background: Prognostic biomarkers remain a focus in colorectal cancer during last decades. There are some studies of E2F transcription factors in different cancer. But the utility of E2F transcription factors as cancer biomarkers in colorectal cancer has not been confirmed. In this research we analyzed multiple databases and performed experimental validation of E2Fs as biomarkers. Methords: Bioinformatics analysis was the main part of this research. Besides, IHC was used to the huamn normal and tumor tissues. Results: Our study showed that the mRNA expression levels of E2F1/3/4/5/6/7/8 were significantly upregulated in carcinoma tissues, whereas E2F2 mRNA was downregulated. High E2F3/4 expression correlated with poor prognosis, whereas high E2F2 expression was correlated with good prognosis. Pathological parameters indicated that expression levels of E2F1/3/5 varied in different tumor stages; however, expression of E2F2/4/6/7/8 did not vary with tumor stage. E2F4 expression was higher in men than women. For pathological type, E2F8 expression was higher in the mucinous adenocarcinoma group compared with the adenocarcinoma group. E2F expression levels were altered in 175 of 524 patients (33%) with colorectal cancer, and the alterations of E2Fs in mucinous adenocarcinoma were more frequent than in adenocarcinoma. Cell cycle was the core function and the most enriched pathway of E2Fs. The functions of E2F2/3/4 may be regulated by some miRNAs. Conclusions: We proved that E2F2/3/4 can be used as prognostic biomarkers for colorectal cancer, and E2F2/3/4 mRNAs may be targeted by some miRNAs to influence “CELL CYCLE” pathway and exert their core functions in colorectal cancer.